Pluxee reports fiscal-year 2026 earnings above expectations, sees 2027 as ’transition year’

More in Business

• HUL’s revenue growth has a party pooper, and it’s may be here to stay

  Strong quarterly sales gains across key consumer categories were overshadowed by heavy margin compression driven by a 24% surge in raw-material expenses. Geopolitical conflict in West Asia has pushed commodity costs higher, prompting price increases and marketing cuts to protect profitability. Management now faces potential volume headwinds as inflationary pressures intersect with drought-affected rural markets.

  2 min read
• STAT+: Biopharma industry at odds over impact of Treasury’s new China rule

  Proposed curbs from the Treasury Department seek to restrict American capital from funding Chinese biotechnology entities. Sector leaders are currently assessing the practical reach of the measure, which surfaced as more aggressive than anticipated. A targeted carve-out for licensing agreements has triggered debate over whether the policy will genuinely hinder Chinese competition or leave substantial avenues open.

  1 min read
• Judge rejects Richard Sacklers' bid to save mansion tied to $7.4B opioid deal

  U.S. Bankruptcy Judge Sean Lane found that attempts to block the real estate transaction conflicted with previously agreed-upon settlement obligations linked to Purdue Pharma's nationwide liabilities. Preserving the property for liquidation ensures that designated collateral continues to fund the multibillion-dollar resolution resulting from the deceptive marketing of OxyContin. The decision marks another procedural loss for the former pharmaceutical executive as courts maintain strict enforcement over pledged ass…

  3 min read